用苯巴比妥治疗镇静催眠药戒断综合征:病例报告

Moayad Alfayoumi , Dore C. Ananthegowda , Asmaa E. Mohamed , Abdulqadir J. Nashwan
{"title":"用苯巴比妥治疗镇静催眠药戒断综合征:病例报告","authors":"Moayad Alfayoumi ,&nbsp;Dore C. Ananthegowda ,&nbsp;Asmaa E. Mohamed ,&nbsp;Abdulqadir J. Nashwan","doi":"10.1016/j.hmedic.2024.100070","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Sedative/hypnotic withdrawal syndrome remains challenging in intensive care units, particularly after prolonged exposure. The sparse literature on this subject makes managing these cases an ongoing challenge. This case report explores phenobarbital's potential as an alternative treatment for sedative-hypnotic withdrawal syndrome, especially when traditional adjunctive treatments prove ineffective.</p></div><div><h3>Case presentation</h3><p>We describe a case of a 26-year-old female admitted with Tuberculous meningitis, who, due to extended sedation, exhibited signs of sedative/hypnotic withdrawal. Phenobarbital was introduced after the patient resisted typical weaning protocols, and her response was closely monitored. Phenobarbital highlighted a rapid onset of action and effective management of withdrawal symptoms. It facilitated the successful weaning of sedation within a short time frame, allowing the patient to transition from ICU without additional sedative treatments.</p></div><div><h3>Conclusion</h3><p>Phenobarbital is a promising alternative in managing sedative/hypnotic withdrawal syndrome, especially in patients who do not respond to standard treatment protocols. However, its usage warrants careful monitoring due to potential side effects. More extensive studies are needed to validate these findings.</p></div>","PeriodicalId":100908,"journal":{"name":"Medical Reports","volume":"5 ","pages":"Article 100070"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949918624000354/pdfft?md5=1114fc719289dc41e0e74735c59ab337&pid=1-s2.0-S2949918624000354-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Sedative-hypnotic withdrawal syndrome treated with phenobarbital: A case report\",\"authors\":\"Moayad Alfayoumi ,&nbsp;Dore C. Ananthegowda ,&nbsp;Asmaa E. Mohamed ,&nbsp;Abdulqadir J. Nashwan\",\"doi\":\"10.1016/j.hmedic.2024.100070\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Sedative/hypnotic withdrawal syndrome remains challenging in intensive care units, particularly after prolonged exposure. The sparse literature on this subject makes managing these cases an ongoing challenge. This case report explores phenobarbital's potential as an alternative treatment for sedative-hypnotic withdrawal syndrome, especially when traditional adjunctive treatments prove ineffective.</p></div><div><h3>Case presentation</h3><p>We describe a case of a 26-year-old female admitted with Tuberculous meningitis, who, due to extended sedation, exhibited signs of sedative/hypnotic withdrawal. Phenobarbital was introduced after the patient resisted typical weaning protocols, and her response was closely monitored. Phenobarbital highlighted a rapid onset of action and effective management of withdrawal symptoms. It facilitated the successful weaning of sedation within a short time frame, allowing the patient to transition from ICU without additional sedative treatments.</p></div><div><h3>Conclusion</h3><p>Phenobarbital is a promising alternative in managing sedative/hypnotic withdrawal syndrome, especially in patients who do not respond to standard treatment protocols. However, its usage warrants careful monitoring due to potential side effects. More extensive studies are needed to validate these findings.</p></div>\",\"PeriodicalId\":100908,\"journal\":{\"name\":\"Medical Reports\",\"volume\":\"5 \",\"pages\":\"Article 100070\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949918624000354/pdfft?md5=1114fc719289dc41e0e74735c59ab337&pid=1-s2.0-S2949918624000354-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949918624000354\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949918624000354","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景镇静剂/催眠药戒断综合征在重症监护病房仍然是一项挑战,尤其是在长期接触镇静剂/催眠药之后。有关这方面的文献很少,因此处理这些病例一直是一项挑战。本病例报告探讨了苯巴比妥作为镇静催眠药戒断综合征替代疗法的潜力,尤其是在传统辅助治疗无效的情况下。病例介绍我们描述了一例因结核性脑膜炎入院的 26 岁女性病例,由于长时间镇静,她出现了镇静催眠药戒断的症状。在患者拒绝接受典型的断药方案后,医生开始使用苯巴比妥,并密切观察她的反应。苯巴比妥起效迅速,能有效控制戒断症状。结论 苯巴比妥是治疗镇静剂/催眠药戒断综合征的一种很有前途的替代药物,尤其是对标准治疗方案无效的患者。然而,由于其潜在的副作用,使用时需要仔细监测。需要进行更广泛的研究来验证这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Sedative-hypnotic withdrawal syndrome treated with phenobarbital: A case report

Background

Sedative/hypnotic withdrawal syndrome remains challenging in intensive care units, particularly after prolonged exposure. The sparse literature on this subject makes managing these cases an ongoing challenge. This case report explores phenobarbital's potential as an alternative treatment for sedative-hypnotic withdrawal syndrome, especially when traditional adjunctive treatments prove ineffective.

Case presentation

We describe a case of a 26-year-old female admitted with Tuberculous meningitis, who, due to extended sedation, exhibited signs of sedative/hypnotic withdrawal. Phenobarbital was introduced after the patient resisted typical weaning protocols, and her response was closely monitored. Phenobarbital highlighted a rapid onset of action and effective management of withdrawal symptoms. It facilitated the successful weaning of sedation within a short time frame, allowing the patient to transition from ICU without additional sedative treatments.

Conclusion

Phenobarbital is a promising alternative in managing sedative/hypnotic withdrawal syndrome, especially in patients who do not respond to standard treatment protocols. However, its usage warrants careful monitoring due to potential side effects. More extensive studies are needed to validate these findings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Thalamic and dentate nuclei involvement in an infant with propofol related infusion syndrome: A case report Gorlin-Goltz syndrome – Report of a case with review of literature Unmasking parvovirus B19: An atypical case of hepatitis with rash and arthralgia Overlap of nephrotic syndrome with nephritic syndrome and its relation to microscopic polyangiitis in a seventeen-year-old young female A rare case of neonatal measles: Reevaluating maternal immunity in the vaccination era
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1